Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John D Sheppard

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Ophthalmology|July 27, 2025
Corneal Staining Responder Analysis: A Clinically Meaningful Dry Eye OutcomeEsen K Akpek, John D Sheppard, Sonja Krösser
Biotechnology Progress|June 4, 2005
A kinetic model for suspended and attached growth of a defined mixed cultureKawai Tam, Mark R Matsumoto, John D Sheppard
Frontiers in Medicine|January 28, 2026
Ocular surface disease following LASIK and cataract surgery: a review of their interrelated complicationsMatthew D Spangler, Nila Kirupaharan, John D Sheppard
Archives of Ophthalmology (Chicago, Ill. : 1960)|July 15, 2009
Modalities to decrease stromal herpes simplex keratitis reactivation ratesJohn D Sheppard, Michael L Wertheimer, Stephen V Scoper
Expert Opinion on Emerging Drugs|November 30, 2021
Emerging therapies for dry eye diseaseLauren Mason, Saad Jafri, Isabelle Dortonne, et al.
Advances in Therapy|March 18, 2016
Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular PressureJohn D Sheppard, Timothy L Comstock, Megan E Cavet
The American Journal of Managed Care|November 6, 2023
A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solutionJohn D Sheppard, David G Evans, Eugene E Protzko
The American Journal of Managed Care|October 16, 2023
Addressing excessive evaporation: an unmet need in dry eye diseasePaul M Karpecki, Kelly K Nichols, John D Sheppard
Eye & Contact Lens|April 18, 2018
Adenovirus Ocular Infections: Prevalence, Pathology, Pitfalls, and Practical PointersDebora Garcia-Zalisnak, Christopher Rapuano, John D Sheppard, et al.
Ophthalmology and Therapy|February 21, 2019
Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in RabbitsJohn D Sheppard, Paul C Cockrum, Angela Justice, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Ophthalmology|July 27, 2025
Corneal Staining Responder Analysis: A Clinically Meaningful Dry Eye OutcomeEsen K Akpek, John D Sheppard, Sonja Krösser
Biotechnology Progress|June 4, 2005
A kinetic model for suspended and attached growth of a defined mixed cultureKawai Tam, Mark R Matsumoto, John D Sheppard
Frontiers in Medicine|January 28, 2026
Ocular surface disease following LASIK and cataract surgery: a review of their interrelated complicationsMatthew D Spangler, Nila Kirupaharan, John D Sheppard
Archives of Ophthalmology (Chicago, Ill. : 1960)|July 15, 2009
Modalities to decrease stromal herpes simplex keratitis reactivation ratesJohn D Sheppard, Michael L Wertheimer, Stephen V Scoper
Expert Opinion on Emerging Drugs|November 30, 2021
Emerging therapies for dry eye diseaseLauren Mason, Saad Jafri, Isabelle Dortonne, et al.
Advances in Therapy|March 18, 2016
Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular PressureJohn D Sheppard, Timothy L Comstock, Megan E Cavet
The American Journal of Managed Care|November 6, 2023
A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solutionJohn D Sheppard, David G Evans, Eugene E Protzko
The American Journal of Managed Care|October 16, 2023
Addressing excessive evaporation: an unmet need in dry eye diseasePaul M Karpecki, Kelly K Nichols, John D Sheppard
Eye & Contact Lens|April 18, 2018
Adenovirus Ocular Infections: Prevalence, Pathology, Pitfalls, and Practical PointersDebora Garcia-Zalisnak, Christopher Rapuano, John D Sheppard, et al.
Ophthalmology and Therapy|February 21, 2019
Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in RabbitsJohn D Sheppard, Paul C Cockrum, Angela Justice, et al.
Pageof 6